Autopsy report · NCT00085410
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
Cause of deathOther
“The trial was discontinued early due to no confirmed partial responses.”
Life of this trial
- Registered 5 months after it had already started.
- Ran for about 6 years 3 months before it stopped.
- 20 participants enrolled.
- Results were posted on the registry 7 years 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct; Adenocarcinoma of the Gallbladder; Advanced Adult Primary Liver Cancer; Gastrointestinal Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
- Interventions
- bortezomib
- Participants
- 20
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.